托珠单抗治疗干扰素α和抗肿瘤坏死因子-α治疗失败的贝赫切特葡萄膜炎。
Tocilizumab for the Treatment of Behçet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy.
机构信息
a Department of Ophthalmology , Istanbul University, Istanbul Faculty of Medicine , Istanbul , Turkey.
b Department of Ophthalmology , Ondokuz Mayis University, Faculty of Medicine , Samsun , Turkey.
出版信息
Ocul Immunol Inflamm. 2018;26(7):1005-1014. doi: 10.1080/09273948.2017.1355471. Epub 2017 Oct 11.
PURPOSE
To report the results of tocilizumab (TCZ) treatment in patients with Behçet uveitis (BU) who had failed conventional, interferon alpha, and anti-Tumor necrosis factor-alpha therapy.
METHODS
We reviewed the records of five patients with BU treated with monthly infusions of TCZ 8 mg/kg. Outcome measures were visual acuity, anterior chamber cells, laser flare meter (LFM) readings, vitreous haze, central macular thickness (CMT), and fluorescein angiography (FA) score.
RESULTS
The clinical inactivity of BU and 20/50 or better vision were achieved in three female and two male patients treated with TCZ for 5-19 months. The mean LFM reading was reduced from 15.4 ± 2.7 to 5.0 ± 0.9 ph/ms; the mean CMT from 324.7 ± 36.6 µm to 280.2 ± 34.1 µm; and the mean FA score from 20.6 ± 5.4 to 9.3 ± 4.5 µm at the last visit. The only side effect was a slight elevation of the total cholesterol level in one patient.
CONCLUSIONS
Tocilizumab may be a safe and effective therapeutic option for refractory BU.
目的
报告托珠单抗（TCZ）治疗常规、干扰素α和抗肿瘤坏死因子-α治疗失败的贝赫切特葡萄膜炎（BU）患者的结果。
方法
我们回顾了 5 例接受 TCZ 8mg/kg 每月输注治疗的 BU 患者的记录。观察指标包括视力、前房细胞、激光闪烁计（LFM）读数、玻璃体混浊、中央黄斑厚度（CMT）和荧光素血管造影（FA）评分。
结果
3 名女性和 2 名男性患者在接受 TCZ 治疗 5-19 个月后，BU 临床活动得到控制，视力达到 20/50 或更好。LFM 读数从 15.4±2.7 降至 5.0±0.9 ph/ms；CMT 从 324.7±36.6µm 降至 280.2±34.1µm；FA 评分从 20.6±5.4 降至最后一次就诊时的 9.3±4.5µm。唯一的副作用是一名患者的总胆固醇水平略有升高。
结论
托珠单抗可能是治疗难治性 BU 的一种安全有效的治疗选择。
Zotero 插件